# US 2016/0243260 A1 · Treatment of neurological diseases using adeno-associated virus (AAV) comprising AAV-5 capsid proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0243260 A1
- Document ID: US20160243260A1
- Status: Published application
- Kind: A1
- Application number: 15/031,782
- Filed: 2014-10-24
- Published: 2016-08-25
- Earliest claimed: 2013-10-24
- Assignees: uniQure IP B.V.
- Applicants: Uniqure IP B.V.
- Inventors: Bas BLITS
- Web page: https://patentgrep.com/patent/US20160243260A1

## CPC

- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- A61K 48/0066: {Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid}
- A61K 48/0083: {characterised by an aspect of the administration regime}
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- A61P 39/02: Antidotes
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/86: Viral vectors
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to methods for treating disorders affecting motor function, such as motor function affected by disease, injury to the brain and/or spinal cord using an adeno-associated virus (AAV) gene therapy vector comprising adeno-associated virus 5 (AAV5) capsid proteins and a gene product of interest flanked by AAV ITRs. In particular, the gene therapy vector of the present invention is administered via injection into the cerebrospinal fluid (CSF), preferably by lumbar injection and/or injection into the cisterna magna.

## Claims

### Claim 1

An adeno-associated virus (AAV) gene therapy vector for use as a medicament in a mammalian subject, wherein the gene therapy vector comprises AAV serotype 5 capsid proteins and a gene product of interest flanked by AAV ITRs and wherein the gene therapy vector is administered by intrathecal lumbar administration.

### Claim 2 (depends on 1)

An AAV gene therapy vector according to claim 1, wherein the intrathecal lumbar administration is at a position selected from the group consisting of: L4-L5, L3-L4, L1-L2 and L2-L3.

### Claim 3 (depends on 1)

An AAV gene therapy vector according to claim 1, wherein the AAV gene therapy vector is a single stranded AAV gene therapy vector or a monomeric duplex vector.

### Claim 4 (depends on 1)

An AAV gene therapy vector according to claim 1, wherein the gene product of interest is for use in the treatment or prophylaxis of a condition selected from the group consisting of: amyotrofic laterale sclerose (ALS), spinal muscular atrophy (SMA), pain, Huntington's disease, Alzheimer's disease, Tay-Says disease, Friedreich ataxia, ataxia telangietacsia, Spinocerebellar ataxia type 1, 2 and 3, Niemann-Pick disease A, B and C, Dopa-responsive dystonia, Fragile X syndrome, Krabbe disease, Glycogen storage disease type 2 (Pompe), Primary lateral sclerosis, Pelizaeus-Merzbacher disease, X-linked adrenoleukodystrophy, Giant axonal neuropathy, Multiple system atrophy (MSA), Proximal myotonic myopathy, Neuronal Ceroid Lipofuscinosis (Batten disease) and cancer.

### Claim 5 (depends on 1)

An AAV gene therapy vector according to claim 1, wherein the AAV ITRs are AAV serotype 2 ITRs.

### Claim 6 (depends on 1)

An AAV gene therapy vector according to claim 1, wherein the gene product of interest is selected from the group consisting of: Aspartylglucosaminidase, α-Galactosidase A, Palmitoyl Protein Thioesterase, Tripeptidyl Peptidase, Lysosomal Transmembrane Protein, Multiple gene products, Cysteine transporter, Acid ceramidase, Acid α-L-fucosidase, Protective protein/cathepsin A, Acid β-glucosidase, or glucocerebrosidase, Acid β-galactosidase, Iduronate-2-sulfatase, α-L-Iduronidase, Galactocerebrosidase, Acid α-mannosidase, Acid β-mannosidase, Arylsulfatase B, Arylsulfatase A, N-Acetylgalactosamine-6-sulfate sulfatase, Acid β-galactosidase, N-Acetylglucosamine-1-phosphotransferase, Acid sphingomyelinase, NPC-1, Acid α-glucosidase, β-Hexosaminidase B, Heparan N-sulfatase, α-N-Acetylglucosaminidase, Acetyl-CoA:α-glucosaminide N-acetyltransferase, N-Acetylglucosamine-6-sulfate sulfatase, α-N-Acetylgalactosaminidase, α-N-Acetylgalactosaminidase, α-Neuramidase, β-Glucuronidase, β-Hexosaminidase A, Acid Lipase, neurotrophic factors such as Nerve Growth Factor (NGF), Neurotrophin-3 (NT-3), Neurotrophin-4/5 (NT-4/5), Brain derived neurotrophic factor (BDNF), Cerebral Dopamine Neurotrophic factor (CDNF), glial cell line-derived neurotrophic factor (GDNF), ciliary neurotrophic factor (CNTF), growth factor Insuline-like growth factor (IGF-1), and miRNA for downregulation of a faulty gene.

### Claim 7 (depends on 1)

An AAV gene therapy vector according to claim 1, wherein the gene product of interest is for use in the treatment or prophylaxis of a condition associated with motor neurons and/or neurons in the DRGs.

### Claim 8 (depends on 1)

An AAV gene therapy vector according to claim 1, wherein the gene product of interest is operably linked to expression control elements comprising a promoter that produces sufficient expression of the gene product of interest to obtain a therapeutic effect, wherein the promoter preferably is selected from the group consisting of: cytomegalovirus (CMV) promoter, phosphoglycerate kinase (PGK), CAG promoter (a combination of the cytomegalovirus early enhancer element and chicken beta-actin promoter), glial fibrilary acidic protein (GFAP) promoter, synapsin-1 promoter, Neuron Specific Enolase (NSE) and inducible promoters such as Gene Switch or a tet-operon derived promoter.

### Claim 9 (depends on 1)

An AAV gene therapy vector according to claim 1, wherein the gene therapy vector is further administered into the Cisterna magna prior to, simultaneous or after the intrathecal lumbar administration.

### Claim 10 (depends on 1)

An AAV gene therapy vector according to claim 1, wherein 2×1013-2×1015 genome copies per kilogram of body weight is administered to the subject.

### Claim 11 (depends on 10)

An AAV gene therapy vector according to claim 10, wherein 8×1013-6×1014 genome copies per kilogram of body weight is administered to the subject.

### Claim 12 (depends on 1)

An AAV gene therapy vector according to claim 1, wherein the subject is not subjected to pretreatment with a substance that controls intracranial pressure and/or can disrupt the intercellular tight junctions between endothelial cells of the CNS microvasculature and/or facilitates delivery of drugs such as chemotherapeutics to the CNS.

### Claim 13 (depends on 1)

An AAV gene therapy vector according to claim 1, wherein the subject is not subjected to intravenous mannitol pretreatment prior to intrathecal lumbar administration of the AAV gene therapy vector.

### Claim 14 (depends on 1)

An AAV gene therapy vector according to claim 1, wherein the mammalian subject is a human.

### Claim 15 (depends on 1)

An AAV gene therapy vector according to claim 1, wherein the AAV gene therapy vector is not a self-complementary gene vector.
